News headlines about Roche (OTCMKTS:SNYNF) have been trending somewhat positive on Friday, according to InfoTrie. The research firm scores the sentiment of news coverage by analyzing more than 6,000 blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Roche earned a media sentiment score of 1.00 on their scale. InfoTrie also gave news headlines about the company an news buzz score of 3 out of 10, indicating that recent news coverage is unlikely to have an impact on the stock’s share price in the immediate future.
Separately, Kepler Capital Markets reissued a “buy” rating on shares of Roche in a report on Wednesday.
SNYNF remained flat at $$100.20 during trading on Friday. The company had a trading volume of 111 shares, compared to its average volume of 12,436. The firm’s 50 day moving average is $100.27 and its 200-day moving average is $92.88. Roche has a 1-year low of $80.80 and a 1-year high of $103.36.
Sanofi provides therapeutic solutions worldwide. It offers Cerezyme and Cerdelga for Gaucher, Myozyme and Lumizyme for Pompe, Fabrazyme for Fabry, and Aldurazyme for mucopolysaccharidosis Type 1; and Aubagio, an immunomodulatory and Lemtrada, a monoclonal antibody for multiple sclerosis. It also provides Dupixent for atopic dermatitis; Kevzara for rheumatoid arthritis; Eloctate and Alprolix to treat hemophilia; and Cablivi to treat acquired thrombotic thrombocytopenic purpura.
Further Reading: Cash Flow
Receive News & Ratings for Roche Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche and related companies with MarketBeat.com's FREE daily email newsletter.